WEKO3
アイテム
A Pilot Study of Comprehensive Genomic Profiling for Pediatric and Adolescent and Young Adult Solid Tumor Patients in Japan
https://dmu.repo.nii.ac.jp/records/5119
https://dmu.repo.nii.ac.jp/records/511934e464b4-e074-40a1-854d-59500c7bb1f6
名前 / ファイル | ライセンス | アクション |
---|---|---|
![]() |
||
![]() |
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
タイトル | ||||||
タイトル | A Pilot Study of Comprehensive Genomic Profiling for Pediatric and Adolescent and Young Adult Solid Tumor Patients in Japan | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | comprehensive genomic profiling | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | pediatric and AYA solid tumor patients | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | precision cancer medicine | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
Matsudera, Shotaro
× Matsudera, Shotaro× Kano, Yoshihito× Aoyagi, Yasuko× Tohyama, Kohki× Ogino, Kei× Okamoto, Kentaro× Yamaguchi, Takeshi× Watanabe, Shun× Nakajima, Masanobu× Morita, Shinji× Nakamura, Takatoshi× Suzuki, Kan× Tsuchioka, Takashi× Kojima, Kazuyuki× Miyake, Satoshi× Takagi, Masatoshi× Ikeda, Sadakazu |
|||||
著者所属 | ||||||
値 | Department of Precision Cancer Medicine, Center for Innovative Cancer Treatment, Tokyo Medical and Dental University;First Department of Surgery, Dokkyo Medical University | |||||
著者所属 | ||||||
値 | Department of Precision Cancer Medicine, Center for Innovative Cancer Treatment, Tokyo Medical and Dental University | |||||
著者所属 | ||||||
値 | Department of Precision Cancer Medicine, Center for Innovative Cancer Treatment, Tokyo Medical and Dental University | |||||
著者所属 | ||||||
値 | Department of Precision Cancer Medicine, Center for Innovative Cancer Treatment, Tokyo Medical and Dental University | |||||
著者所属 | ||||||
値 | Department of Specialized Surgeries, Tokyo Medical and Dental University | |||||
著者所属 | ||||||
値 | Department of Specialized Surgeries, Tokyo Medical and Dental University | |||||
著者所属 | ||||||
値 | First Department of Surgery, Dokkyo Medical University | |||||
著者所属 | ||||||
値 | First Department of Surgery, Dokkyo Medical University | |||||
著者所属 | ||||||
値 | First Department of Surgery, Dokkyo Medical University | |||||
著者所属 | ||||||
値 | First Department of Surgery, Dokkyo Medical University | |||||
著者所属 | ||||||
値 | First Department of Surgery, Dokkyo Medical University | |||||
著者所属 | ||||||
値 | First Department of Surgery, Dokkyo Medical University | |||||
著者所属 | ||||||
値 | First Department of Surgery, Dokkyo Medical University | |||||
著者所属 | ||||||
値 | First Department of Surgery, Dokkyo Medical University | |||||
著者所属 | ||||||
値 | Department of Precision Cancer Medicine, Center for Innovative Cancer Treatment, Tokyo Medical and Dental University | |||||
著者所属 | ||||||
値 | Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University | |||||
著者所属 | ||||||
値 | Department of Precision Cancer Medicine, Center for Innovative Cancer Treatment, Tokyo Medical and Dental University;Moores Cancer Center, University of California | |||||
書誌情報 |
Dokkyo Medical Journal 巻 1, 号 1, p. 56-62, 発行日 2022-03 |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Introduction: Comprehensive genomic profiling (CGP) was widely adopted in Japan after its coverage by national healthcare insurance began in June 2019. We investigated the clinical utility of CGP in pediatric and adolescent young adults (AYA) solid tumor patients. Materials and Methods: Between November 2017 and December 2019, 13 patients who progressed with or who were likely to progress with standard therapies were recruited to the PROFILE-F study to undergo CGP using either FoundationOneⓇ CDx or FoundationOneⓇ Heme. Results: The median age was 28 years old. Tumor types were as follows: neuroblastoma (n = 1), Wilms’ tumor (n = 1), rhabdomyosarcoma (n = 2), Ewing sarcoma (n = 1), gastric cancer (n = 1), rectal cancer (n = 1), osteosarcoma (n = 1), neuroendocrine tumor (n = 2), salivary gland carcinoma (n = 1), tracheal adenoid cystic carcinoma (n = 1), and thymic cancer (n = 1). In 92% of cases, at least one genomic alteration was identified, including CDKN2A (four cases), TP53 (three cases), and MYC (two cases). Actionable aberrations were found in 10 cases (77%), and a clinical trial candidate was found in seven cases (54%). However, no patients were able to receive biomarker-matched therapy according to their genomic alterations. Conclusions: Further efforts to increase basket trials and collection of clinical genomic data to predict response are necessary to advance precision cancer medicine and surgical management in pediatric and AYA populations. |
|||||
記事種別 | ||||||
値 | Original | |||||
出版者 | ||||||
出版者 | Dokkyo Medical Society | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 2436-5211 | |||||
DOI | ||||||
識別子タイプ | DOI | |||||
関連識別子 | 10.51040/dkmj.1.1_56 |